---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-21-000039"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2021-07-27T23:59:59+00:00"
generated_at: "2026-06-30T02:15:14.805233+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics settles all patent litigation with Bio-Rad, enters global cross-license for single cell analysis

## Summary
- Cross license covers single cell analysis; excludes spatial, in situ, and digital PCR (for 10x).
- 10x to pay Bio-Rad $29.4M in royalties/interest for past GEM sales; $15.4M reversal in Q2 2021.
- Future royalty payments expected to impact gross margins by less than 1% through 2030.
- All outstanding litigation dismissed with prejudice.
- Agreement term is life of licensed patents.

## SEC filing metadata
- accession: 0001770787-21-000039
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2021-07-27T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078721000039/0001770787-21-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078721000039/txg-20210726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-21-000039
- JSON: https://secwatch.observer/filing/0001770787-21-000039.json
- Plain text: https://secwatch.observer/filing/0001770787-21-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.